BioMarin Pharmaceuticals BMRN Number of commercial therapies
Number of commercial therapies at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept bmrn:NumberOfCommercialTherapies.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed May 2, 2025.
- Filed
- May 2, 2025
- Fiscal quarter
- Q1 FY2025
- Calendar quarter
- Q1 2025
- Accession
- 0001048477-25-000051
BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult to treat genetic conditions.
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's number of commercial therapies?
- BioMarin Pharmaceuticals (BMRN) reported number of commercial therapies of $8 in Q1 2025.
- What does number of commercial therapies mean?
- Number of commercial therapies as reported by BioMarin Pharmaceuticals Inc.
Ask your AI about BioMarin Pharmaceuticals's number of commercial therapies.
Connect your AI assistant and compare it to peers, right in your chat.
